Premium
Evaluation of 211 At‐labelled monodisperse polymer particles in vivo : Comparison of different specific activities
Author(s) -
Larsen Roy H.,
Varaas Tone,
Hoff Per,
Vergote Ignace B.,
Alstad Jorolf,
De Vos Laure N.,
Nustad Kjell
Publication year - 1996
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/(sici)1099-1344(199609)38:9<775::aid-jlcr896>3.0.co;2-u
Subject(s) - chemistry , in vivo , dispersity , specific activity , pharmacology , biochemistry , enzyme , organic chemistry , medicine , microbiology and biotechnology , biology
Abstract The α‐particle emitter 211 At was covalently coupled to 1.8 μm aminated monodisperse polymer particles (MDPP) and used to irradiate the intraperitoneal cavity in mice with disseminated tumour cells. Specific activity has previously been shown to influence the therapeutic efficacy of α‐particle emitting compounds and the therapeutic efficacy of 211 At‐MDPP with various specific activity was therefore investigated. Groups of mice (10 animals per group) were treated with intraperitoneal injections of 100 kBq of 211 At‐MDPP with specific activities of 0.19, 0.55, 1.7, 5.0, 15, and 45 MBq/mg. A significantly prolonged survival was observed in the treated groups compared to the control group (from 19 to 26 days vs. 12 days, median). The difference in survival between the 211 At‐MDPP treated groups was not significant, but some animals with short survival were observed in the groups that had received the 0.19, 15 and 45 MBq/mg preparations. K13 monoclonal antibody values, which are an indicator of tumour growth, were high in some animals in the 15 and 45 MBq/mg groups (day 7 values).